TrialCancer2014

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Philip A Philip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.